|
Other Operating Expense Net (Narrative) (Details) (USD $)
In Millions, unless otherwise specified |
6 Months Ended |
|---|---|
|
Jun. 29, 2012
|
|
|
Orthopaedic facility optimization [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Activities, Description | In 2010, the Company began updating its Indianapolis, IN facility to streamline operations, consolidate two buildings, increase capacity, further expand capabilities and reduce dependence on outside suppliers. This initiative was completed in 2011. In 2011, the Company began construction on an orthopaedic manufacturing facility in Fort Wayne, IN and will transfer the manufacturing operations currently being performed at its Columbia City, IN location into this new facility. The construction of the Fort Wayne facility was completed in June 2012 and the transfer of operations from the Columbia City facility is expected to be completed in the third quarter of 2012. In the third quarter of 2012, the Company finalized plans to transfer most major functions currently performed at its facilities in Orvin and Corgemont, Switzerland into existing facilities in Fort Wayne, IN and Tijuana, Mexico by the end of 2013. |
| Restructuring Initiation Date | 2010 |
| Restructuring And Related Activities Capital Expenditures Incurred To Date | $ 22.0 |
| Restructuring and Related Cost, Cost Incurred to Date | 3.0 |
|
Orthopaedic facility optimization [Member] | Other [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 1.0 |
|
Orthopaedic facility optimization [Member] | Minimum [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring And Related Activities Expected Capital Expenditures | 30.0 |
| Restructuring and Related Cost, Expected Cost | 30.0 |
|
Orthopaedic facility optimization [Member] | Minimum [Member] | Severance and retention [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 11.0 |
|
Orthopaedic facility optimization [Member] | Minimum [Member] | Production inefficiencies, moving and revalidation [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 3.0 |
|
Orthopaedic facility optimization [Member] | Minimum [Member] | Accelerated depreciation and asset write-offs [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 10.0 |
|
Orthopaedic facility optimization [Member] | Minimum [Member] | Personnel [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 5.0 |
|
Orthopaedic facility optimization [Member] | Maximum [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring And Related Activities Expected Capital Expenditures | 40.0 |
| Restructuring and Related Cost, Expected Cost | 36.0 |
|
Orthopaedic facility optimization [Member] | Maximum [Member] | Severance and retention [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 13.0 |
|
Orthopaedic facility optimization [Member] | Maximum [Member] | Production inefficiencies, moving and revalidation [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 4.0 |
|
Orthopaedic facility optimization [Member] | Maximum [Member] | Accelerated depreciation and asset write-offs [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 12.0 |
|
Orthopaedic facility optimization [Member] | Maximum [Member] | Personnel [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 6.0 |
|
Medical device facility optimization [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Activities, Description | Near the end of 2011, the Company initiated plans to upgrade and expand its manufacturing infrastructure in order to support its medical device strategy. This will include the transfer of certain product lines to create additional capacity for the manufacture of medical devices, expansion of two existing facilities, as well as the purchase of equipment to enable the production of medical devices. These initiatives are expected to be completed over the next two to three years. |
| Restructuring Initiation Date | 2011 |
| Restructuring And Related Activities Capital Expenditures Incurred To Date | 3.9 |
| Restructuring and Related Cost, Cost Incurred to Date | 0.9 |
|
Medical device facility optimization [Member] | Other [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 1.0 |
|
Medical device facility optimization [Member] | Minimum [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring And Related Activities Expected Capital Expenditures | 15.0 |
| Restructuring and Related Cost, Expected Cost | 2.0 |
|
Medical device facility optimization [Member] | Minimum [Member] | Production inefficiencies, moving and revalidation [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 0.5 |
|
Medical device facility optimization [Member] | Minimum [Member] | Personnel [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 1.0 |
|
Medical device facility optimization [Member] | Maximum [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring And Related Activities Expected Capital Expenditures | 20.0 |
| Restructuring and Related Cost, Expected Cost | 3.0 |
|
Medical device facility optimization [Member] | Maximum [Member] | Production inefficiencies, moving and revalidation [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 1.0 |
|
Medical device facility optimization [Member] | Maximum [Member] | Personnel [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 1.5 |
|
ERP system upgrade [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Activities, Description | In 2011, the Company initiated plans to upgrade its existing global ERP system. This initiative is expected to be completed over the next two years. |
| Restructuring Initiation Date | 2011 |
| Restructuring And Related Activities Capital Expenditures Incurred To Date | 2.0 |
| Restructuring and Related Cost, Cost Incurred to Date | 2.8 |
|
ERP system upgrade [Member] | Minimum [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring And Related Activities Expected Capital Expenditures | 4.0 |
| Restructuring and Related Cost, Expected Cost | 5.0 |
|
ERP system upgrade [Member] | Minimum [Member] | Training And Consulting Costs [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 3.0 |
|
ERP system upgrade [Member] | Minimum [Member] | Accelerated depreciation and asset write-offs [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 2.0 |
|
ERP system upgrade [Member] | Maximum [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring And Related Activities Expected Capital Expenditures | 5.0 |
| Restructuring and Related Cost, Expected Cost | 7.0 |
|
ERP system upgrade [Member] | Maximum [Member] | Training And Consulting Costs [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 4.5 |
|
ERP system upgrade [Member] | Maximum [Member] | Accelerated depreciation and asset write-offs [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring and Related Cost, Expected Cost | 2.5 |
|
Corporate Headquarters Relocation [Member]
|
|
| Restructuring Cost and Reserve [Line Items] | |
| Restructuring Initiation Date | second quarter of 2012 |
| Restructuring and Related Cost, Cost Incurred to Date | $ 1.2 |